Aptamer Group Ltd Revenue and Competitors

York,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Aptamer Group Ltd's estimated annual revenue is currently $8.1M per year.(i)
  • Aptamer Group Ltd's estimated revenue per employee is $155,000

Employee Data

  • Aptamer Group Ltd has 52 Employees.(i)
  • Aptamer Group Ltd grew their employee count by -15% last year.

Aptamer Group Ltd's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Director & CTOReveal Email/Phone
3
Automation and Technical Support DirectorReveal Email/Phone
4
Operations Project ManagerReveal Email/Phone
5
Senior Cell Culture ScientistReveal Email/Phone
6
Senior Selection ScientistReveal Email/Phone
7
Senior Selection ScientistReveal Email/Phone
8
Senior Selection ScientistReveal Email/Phone
9
Business Development Associate DirectorReveal Email/Phone
10
Production ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Aptamer Group Ltd?

Aptamer Group brings together various aptamer technology driven companies to provide a range of services to the life sciences industry. Over the coming decades aptamer technology will have a profound effect on the life science market helping provide more cost-effective solutions to end users. We aim to address market needs through our group which has companies specialising in: the provision of high quality R&D consumables and high throughput aptamer screening services through Aptasol, biomarker discovery and validation tools (Aptasort), diagnostics devices / reagents (Aptadx) and therapeutic lead compounds (Aptarx). Aptamers are nucleic acid molecules made from DNA or RNA. Aptamers bind to other molecules with a higher degree of specificity and sensitivity than antibodies. Aptamers also have few of the drawbacks associated with antibodies, making them suitable replacements in many applications. The aptamers we develop are used in a variety of areas of life sciences research ranging from R&D consumables; such as, fluorescence microscopy &, flow cytometry probes through to purification (immunoprecipitation-like) reagents. We develop aptamers for use in clinical and non-clinical diagnostics and as candidate molecules for targeted therapeutics. We have also developed a first in-kind biomarker discovery process, which is set to breathe new life into the proteomics market. Our aptamers are currently being used in a variety of scenarios where antibodies have failed and are being expertly combined with microfluidics, electrochemical sensors and various nanotechnologies. The manufacturing costs and development times for monoclonal antibodies are several times higher and several times longer than the corresponding aptamer-based solution. Low manufacturing costs and speed of delivery means aptamers can be used at some point along the drug discovery process to facilitate the development of diagnostics and treatments. Get our newsletter: https://aptamergroup.com/newsletter

keywords:N/A

N/A

Total Funding

52

Number of Employees

$8.1M

Revenue (est)

-15%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Aptamer Group Ltd News

2022-04-20 - Global Targeted Drug Delivery Market to Surpass US$ 22,704 Million by 2030, Says Coherent Market Insights (CMI)

... had signed an agreement with Aptamer Group, a leading provider of ... Suda Limited, Vectura Group PLC, Taiwan Liposome Company, Ltd.,...

2022-03-30 - UK economy, S4 Capital and Provident Financial lead the line of Thursday"s announcements

Interim results: Aptamer Group PLC (AIM:APTA), ... Provident Financial (LSE:PFG) Group PLC, Reach plc, RTW Venture Fund Ltd (LSE:RTWG) , S4...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$13.6M52-13%N/A
#2
$10.3M522%N/A
#3
$13.6M526%N/A
#4
$12.6M526%N/A
#5
$12.9M53-2%N/A